{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:39:19Z","timestamp":1756463959965,"version":"3.41.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T00:00:00Z","timestamp":1431475200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s00228-015-1855-6","type":"journal-article","created":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T05:59:55Z","timestamp":1431410395000},"page":"835-841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems"],"prefix":"10.1007","volume":"71","author":[{"given":"Rui","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haotian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,13]]},"reference":[{"issue":"3","key":"1855_CR1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/14656566.2012.652085","volume":"13","author":"S Gibiino","year":"2012","unstructured":"Gibiino S, Serretti A (2012) Paroxetine for the treatment of depression: a critical update. Expert Opin Pharmacother 13(3):421\u2013431","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"1855_CR2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1055\/s-2005-864121","volume":"38","author":"M Gilles","year":"2005","unstructured":"Gilles M, Deuschle M, Kellner S et al (2005) Paroxetine serum concentrations in depressed patients and response to treatment. Pharmacopsychiatry 38(3):118\u2013121","journal-title":"Pharmacopsychiatry"},{"issue":"8","key":"1855_CR3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/hup.1252","volume":"26","author":"N Yasui-Furukori","year":"2011","unstructured":"Yasui-Furukori N, Nakagami T, Kaneda A et al (2011) Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders. Hum Psychopharmacol 26(8):602\u2013608","journal-title":"Hum Psychopharmacol"},{"key":"1855_CR4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1600-0447.1989.tb07176.x","volume":"350","author":"CM Kaye","year":"1989","unstructured":"Kaye CM, Haddock RE, Langley PF et al (1989) A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 350:60\u201375","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"3","key":"1855_CR5","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1124\/dmd.109.030551","volume":"38","author":"J Jornil","year":"2010","unstructured":"Jornil J, Jensen KG, Larsen F, Linnet K (2010) Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos 38(3):376\u2013385","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1855_CR6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2133\/dmpk.DMPK-11-RV-121","volume":"27","author":"LK Ten","year":"2012","unstructured":"Ten LK, Bertilsson L (2012) Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet 27(1):55\u201367","journal-title":"Drug Metab Pharmacokinet"},{"key":"1855_CR7","unstructured":"http:\/\/www.cypalleles.ki.se\/"},{"issue":"5","key":"1855_CR8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.2013.2","volume":"93","author":"JK Hicks","year":"2013","unstructured":"Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, M\u00fcller DJ, Gaedigk A, Stingl JC (2013) Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 93(5):402\u2013408","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1855_CR9","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3109\/09540261.2013.825581","volume":"25","author":"A Gaedigk","year":"2013","unstructured":"Gaedigk A (2013) Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry 25(5):534\u2013553","journal-title":"Int Rev Psychiatry"},{"issue":"2","key":"1855_CR10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","volume":"83","author":"A Gaedigk","year":"2008","unstructured":"Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83(2):234\u2013242","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1855_CR11","first-page":"121","volume":"28","author":"J Saruwatari","year":"2014","unstructured":"Saruwatari J (2014) Nakashima H1, Tsuchimine S2, Nishimura M1, Ogusu N1, Yasui-Furukori N2. Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders. Pharmgenomics Pers Med 28(7):121\u2013127","journal-title":"Pharmgenomics Pers Med"},{"issue":"10","key":"1855_CR12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/11318050-000000000-00000","volume":"48","author":"FF Ververs","year":"2009","unstructured":"Ververs FF, Voorbij HA, Zwarts P, Belitser SV, Egberts TC, Visser GH, Schobben AF (2009) Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clin Pharmacokinet 48(10):677\u2013683","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1855_CR13","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/FTD.0b013e31817d6f5d","volume":"30","author":"M Gex-Fabry","year":"2008","unstructured":"Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, Bertschy G (2008) CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 30(4):474\u2013482","journal-title":"Ther Drug Monit"},{"issue":"5","key":"1855_CR14","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1365-2125.2008.03267.x","volume":"66","author":"KS Lim","year":"2008","unstructured":"Lim KS, Cho JY, Jang IJ, Kim BH, Kim J, Jeon JY, Tae YM, Yi S, Eum S, Shin SG, Yu KS (2008) Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects. Br J Clin Pharmacol 66(5):660\u2013666","journal-title":"Br J Clin Pharmacol"},{"issue":"14","key":"1855_CR15","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2217\/pgs.13.160","volume":"14","author":"JC Qian","year":"2013","unstructured":"Qian JC, Xu XM, Hu GX, Dai DP, Xu RA, Hu LM, Li FH, Zhang XH, Yang JF, Cai JP (2013) Genetic variations of human CYP2D6 in the Chinese Han population. Pharmacogenomics 14(14):1731\u20131743","journal-title":"Pharmacogenomics"},{"key":"1855_CR16","unstructured":"http:\/\/frodo.wi.mit.edu\/primer3"},{"issue":"4","key":"1855_CR17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10928-012-9253-5","volume":"39","author":"HD Yoo","year":"2012","unstructured":"Yoo HD, Cho HY, Lee SN, Yoon H, Lee YB (2012) Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1. J Pharmacokinet Pharmacodyn 39(4):329\u2013341","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"7","key":"1855_CR18","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1124\/dmd.108.022368","volume":"37","author":"SJ Lee","year":"2009","unstructured":"Lee SJ, Lee SS, Jung HJ, Kim HS, Park SJ, Yeo CW, Shin JG (2009) Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans. Drug Metab Dispos 37(7):1464\u20131470","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1855_CR19","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s00216-010-4101-1","volume":"398","author":"AL Nuijs van","year":"2010","unstructured":"van Nuijs AL, Tarcomnicu I, Simons W, Bervoets L, Blust R, Jorens PG, Neels H, Covaci A (2010) Optimization and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the determination of 13 top-prescribed pharmaceuticals in influent wastewater. Anal Bioanal Chem 398(5):2211\u20132222","journal-title":"Anal Bioanal Chem"},{"issue":"2","key":"1855_CR20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.chroma.2006.02.038","volume":"1114","author":"MJ G\u00f3mez","year":"2006","unstructured":"G\u00f3mez MJ, Petrovi\u0107 M, Fern\u00e1ndez-Alba AR, Barcel\u00f3 D (2006) Determination of pharmaceuticals of various therapeutic classes by solid-phase extraction and liquid chromatography-tandem mass spectrometry analysis in hospital effluent wastewaters. J Chromatogr A 1114(2):224\u2013233","journal-title":"J Chromatogr A"},{"issue":"3","key":"1855_CR21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/mp.2012.42","volume":"18","author":"JC Stingl","year":"2013","unstructured":"Stingl JC, Brockm\u00f6ller J, Viviani R (2013) Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry 18(3):273\u2013287","journal-title":"Mol Psychiatry"},{"issue":"5","key":"1855_CR22","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1365-2125.2011.03905.x","volume":"71","author":"JS Lim","year":"2011","unstructured":"Lim JS, Chen XA, Singh O, Yap YS, Ng RC, Wong NS, Wong M, Lee EJ, Chowbay B (2011) Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol 71(5):737\u2013750","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1855_CR23","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00008571-200008000-00010","volume":"10","author":"Y Nishida","year":"2000","unstructured":"Nishida Y, Fukuda T, Yamamoto I, Azuma J (2000) CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics 10(6):567\u2013570","journal-title":"Pharmacogenetics"},{"issue":"2","key":"1855_CR24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/gtmb.2011.0084","volume":"16","author":"LJ Zuo","year":"2012","unstructured":"Zuo LJ, Guo T, Xia DY, Jia LH (2012) Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations. Genet Test Mol Biomarkers 16(2):102\u2013108","journal-title":"Genet Test Mol Biomarkers"},{"issue":"7","key":"1855_CR25","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/clinchem\/48.7.983","volume":"48","author":"L Ji","year":"2002","unstructured":"Ji L, Pan S, Marti-Jaun J, H\u00e4nseler E, Rentsch K, Hersberger M (2002) Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin Chem 48(7):983\u2013988","journal-title":"Clin Chem"},{"issue":"3","key":"1855_CR26","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/clpt.1992.23","volume":"51","author":"SH Sindrup","year":"1992","unstructured":"Sindrup SH, Br\u00f8sen K, Gram LF et al (1992) The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 51(3):278\u2013287","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1855-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-015-1855-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1855-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T23:09:05Z","timestamp":1748387345000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-015-1855-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,13]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["1855"],"URL":"https:\/\/doi.org\/10.1007\/s00228-015-1855-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2015,5,13]]}}}